Literature DB >> 26162406

GEP-NETs UPDATE: Secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers.

Wieke H M Verbeek1, Catharina M Korse1, Margot E T Tesselaar2.   

Abstract

Neuroendocrine tumours (NETs) are rare tumours with an annual incidence in the population in a range of 2-5 new cases per 100,000 inhabitants. NETs are widely variable in terms of anatomical location, hormone production, clinical behaviour and syndromes they can cause. This article reviews the many localizations and clinical presentations of NETs with a main focus on clinical biomarkers and their use in medical practice.
© 2016 European Society of Endocrinology.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26162406     DOI： 10.1530/EJE-14-0971

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN： 0804-4643            Impact factor:   6.664


  9 in total

Review 1.  Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

Review 2.  Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors.

Authors:  Sergio Pedraza-Arévalo; Manuel D Gahete; Emilia Alors-Pérez; Raúl M Luque; Justo P Castaño
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

3.  Clinical Validation of a Pixon-Based Reconstruction Method Allowing a Twofold Reduction in Planar Images Time of 111In-Pentetreotide Somatostatin Receptor Scintigraphy.

Authors:  Philippe Thuillier; David Bourhis; Philippe Robin; Nathalie Keromnes; Ulrike Schick; Pierre-Yves Le Roux; Véronique Kerlan; Philippe Chaumet-Riffaud; Pierre-Yves Salaün; Ronan Abgral
Journal:  Front Med (Lausanne)       Date:  2017-08-30

4.  Neurotensin Receptor 3/Sortilin Contributes to Tumorigenesis of Neuroendocrine Tumors Through Augmentation of Cell Adhesion and Migration.

Authors:  Ji Tae Kim; Dana L Napier; Heidi L Weiss; Eun Y Lee; Courtney M Townsend; B Mark Evers
Journal:  Neoplasia       Date:  2017-12-19       Impact factor: 5.715

Review 5.  Chromogranin A as a valid marker in oncology: Clinical application or false hopes?

Authors:  Stavros Gkolfinopoulos; Konstantinos Tsapakidis; Konstantinos Papadimitriou; Demetris Papamichael; Panteleimon Kountourakis
Journal:  World J Methodol       Date:  2017-03-26

6.  Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.

Authors:  Mengzhen Zheng; Yan Li; Tong Li; Lianfeng Zhang; Lin Zhou
Journal:  Cancer Med       Date:  2019-07-22       Impact factor: 4.452

7.  CLEC3A, MMP7, and LCN2 as novel markers for predicting recurrence in resected G1 and G2 pancreatic neuroendocrine tumors.

Authors:  Masami Miki; Takamasa Oono; Nao Fujimori; Takehiro Takaoka; Ken Kawabe; Yoshihiro Miyasaka; Takao Ohtsuka; Daisuke Saito; Masafumi Nakamura; Yasuyuki Ohkawa; Yoshinao Oda; Mikita Suyama; Tetsuhide Ito; Yoshihiro Ogawa
Journal:  Cancer Med       Date:  2019-05-25       Impact factor: 4.452

8.  Well-differentiated neuroendocrine tumor of the stomach: A rare case at an uncommon site.

Authors:  Burak Gumuscu; Kevin Norwood; George A Parker; C Lee Bridges; Carl B Rountree
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

9.  Cardiovascular Mortality Risk among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Registry-Based Analysis.

Authors:  Shenghong Sun; Wei Wang; Chiyi He
Journal:  Oxid Med Cell Longev       Date:  2021-06-26       Impact factor: 6.543
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.